Sapiens Announces Receipt of Permit from Israel Securities Authority to Publish Prospectus in Israel

Thursday December 4, 7:05 am ET

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 4, 2003--Sapiens International Corporation (Nasdaq:SPNS - News and TASE:SPNS), today announced that it has received a permit from the Israel Securities Authority to publish a prospectus in Israel, under which it will offer to the public in Israel the following securities:
Up to 100,000 units, each consisting of 800 Debentures (Series A), two Options (Series A) exercisable into Debentures (Series A) and six Warrants (Series 1) exercisable into common shares of Sapiens.

The price of each unit will be determined by a tender to be held on December 10, 2003, subject to a minimum of price of NIS 752 (approximately $170) per unit. The offering is secured by an underwriting commitment. Completion of the offering is subject to certain conditions, including that after the public offering the holdings of the Debentures (Series A) meet the minimum dispersal rules of the Tel Aviv Stock Exchange ("TASE").

The following is a description of the main terms of the securities offered under the prospectus:

The Debentures (Series A) are linked to the US dollar and bear annual interest at the rate of 6.0%, payable on the 5th of June and the 5th of December each year commencing on June 5, 2004. Principal is payable in four installment on the 5th of December of the years 2006-2009. During the period beginning 45 days after the registration of the Debentures (Series A) for trading on TASE and ending December 21, 2009, the Debentures (Series A) are convertible in common shares at a conversion rate of one common share per each NIS 27 (approximately $6.10) amount of the Debentures. The conversion rate is subject to certain adjustments. The Debentures (Series A) are unsecured.

Each Option (Series A) is exercisable into 100 Debentures (Series A) no later than March 3, 2004 for an exercise price of NIS 96 (approximately $21.70).

Each Warrant (Series 1) is exercisable into one common share of the Company during the period beginning 45 days after the registration of the Debentures (Series A) for trading on TASE and ending November 16, 2007 for an exercise price of NIS 27 (approximately $6.10) linked to the US dollar.

Sapiens intends to use the net proceeds from the offering to finance its activities and those of its subsidiaries in accordance with the decisions of its Board of Directors from time to time.

The offering is made to the public in Israel only in accordance with Israeli securities laws. It is not open to persons resident in the United States or to other US persons (other than distributors).

The securities offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such Act or an applicable exemption from registration.

About Sapiens
Sapiens International Corporation (Nasdaq and TASE:SPNS), a member of the Formula Group of companies, is a leading global provider of proven IT solutions that modernize business processes and enable insurance organizations to adapt quickly to change. Sapiens' innovative solutions are widely recognized for their ability to cost-effectively align IT with the business demands for speed, flexibility and efficiency. Sapiens operates through its subsidiaries in North America, United Kingdom, EMEA and Asia Pacific and has partnerships with market leaders such as IBM and EDS. Sapiens' clients include Allianz Group, AXA, Liverpool Victoria, Menora, Norwich Union, OneBeacon, Principal Financial, Prudential, Abbey National, ING, Occidental Fire & Casualty, among others. For more information, please visit http://www.sapiens.com.

Except for historical information contained herein, the matters set forth in this release are forward-looking statements that are dependent on certain risks and uncertainties, including such factors, among others, as market acceptance, market demand, pricing, changing regulatory environment, changing economic conditions, risks in new product and service development, the effect of the company's accounting policies and other risk factors detailed in the Company's SEC filings.

Contact:
Sapiens International
Yuval Hadari, +1-877-554-2426
   +972-8-938-2721
yuval.h@sapiens.com
or
Itzick Sharir, +44-1895-464 265
itzick.s@sapiens.com